Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 2, 2015
Pharmacy Choice - News - Pharmaceutical Development - March 2, 2015

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/2/15 - Anticoagulant linked with lower risk of death following heart attack compared to heparin
By a News Reporter-Staff News Editor at Clinical Trials Week Patients who experienced a certain type of heart attack who received the anticoagulant fondaparinux had a lower risk of major bleeding events and death both in the hospital and after six months compared to patients who received low-molecular-weight heparin, although both groups had simi
3/2/15 - Ardelyx Posts 4th Quarter and Full Year 2014 Financial Results [Professional Services Close - Up]
Ardelyx reported financial results for the fourth quarter and twelve months ended December 31, 2014. "We continue to work diligently with AstraZeneca to support the clinical development for tenapanor, and plan to report the results of the Phase 2 a clinical trial in CKD patients in the second quarter of 2015. We are also accelerating the developme
3/2/15 - Athersys and Chugai Enter License Agreement and Collaboration to Develop MultiStem Cell Therapy for Ischemic Stroke in Japan
Release date- 02032015- Athersys, Inc. and Chugai Pharmaceutical Co., Ltd. have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan. Athersys' proprietary cell therapy product, MultiStem, is currently being evaluated in a Phase 2 clinical study for ischemic strok
3/2/15 - Dipexium Pharmaceuticals Announces Successful Completion and Initial Results of Phase 1 Skin Sensitization Trial of Locilex
By a News Reporter-Staff News Editor at Anti-Infectives Week Dipexium Pharmaceuticals, Inc., announced successful completion and initial results of DPX-120, a Phase 1 skin sensitization trial of Locilex , the Company's novel, broad-spectrum topical antibiotic peptide. Visual skin irritation assessments were performed by trained and blinded...
3/2/15 - Dr. Eric Rowinsky joins Mitra Biotech's Scientific Advisory Board
Eric Rowinsky was previously the Chief Medical Officer for ImClone Systems. Dr. Rowinsky is currently the Chief Medical Officer and Head of Research and Development of Stemline Therapeutics, Inc. Dr. Rowinsky has more than 25 years of experience managing clinical trials and developing drugs in oncology, including leading FDA approval of Erbitux
3/2/15 - ENGAGE Randomized Clinical Trial Evaluating Cerdelga eliglustat for Treatment-Naive Patients with Gaucher Disease Type 1 Published in The Journal of...
ENGAGE Randomized Clinical Trial Evaluating Cerdelga eliglustat for Treatment-Naive Patients with Gaucher Disease Type 1 Published in The Journal of the American Medical Association. By a News Reporter-Staff News Editor at Biotech Business Week Genzyme, a Sanofi company, announced the publication of results from the ENGAGE registration study..
3/2/15 - FDA Grants Genentech's Cobimetinib Priority Review for Use in Combination with Zelboraf Vemurafenib in Advanced Melanoma
By a News Reporter-Staff News Editor at Biotech Business Week Genentech, a member of the Roche Group, announced the U.S. Food and Drug Administration has accepted and granted Priority Review for the company's New Drug Application for cobimetinib in combination with Zelboraf for the treatment of people with BRAF V600 mutation-positive advanced
3/2/15 - Findings in the Area of Psoriasis Reported from Nottingham University Hospital NHS Trust (Biological Therapies for the Treatment of Severe Psoriasis...
Findings in the Area of Psoriasis Reported from Nottingham University Hospital NHS Trust. By a News Reporter-Staff News Editor at Clinical Trials Week New research on Papulosquamous Skin Diseases is the subject of a report. Our news journalists obtained a quote from the research from Nottingham University Hospital NHS Trust, "To assess the potent
3/2/15 - Hokkaido University Hospital Reports Findings in Interstitial Lung Disease (The efficacy of tacrolimus in patients with interstitial lung diseases...
According to news originating from Sapporo, Japan, by NewsRx correspondents, research stated, "Interstitial lung diseases complicated with PM or DM are frequently aggressive and refractory to treatment. Our news journalists obtained a quote from the research from Hokkaido University Hospital, "However, little evidence has yet shown the efficacy of.
3/2/15 - Lilly Provides Update on Evacetrapib Phase 3 Trial
By a News Reporter-Staff News Editor at Pharma Business Week Eli Lilly and Company has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months. Last patient visit in..
3/2/15 - Lymphoseek Results from Phase 3 Clinical Trial in Oral Cavity Cancer of the Head and Neck Published in Annals of Surgical Oncology
By a News Reporter-Staff News Editor at Pharma Business Week Navidea Biopharmaceuticals, Inc., announced the peer-reviewed publication of results from a Phase 3 clinical trial of Lymphoseek injection in patients with certain head and neck cancer in the journal Annals of Surgical Oncology. This procedure, however, is quite invasive and carries
3/2/15 - MAGE genes provide insight into optimizing chemotherapy, UT Southwestern cancer researchers find
By a News Reporter-Staff News Editor at Clinical Trials Week DALLAS- UT Southwestern Medical Center scientists have identified a new biomarker that could help identify patients who are more likely to respond to certain chemotherapies. Ryan Potts, Assistant Professor of Physiology, Biochemistry, and Pharmacology, and a member of the Harold C. Simm
3/2/15 - MediVector Completes Patient Enrollment in Two Phase 3 Studies of Favipiravir for Influenza
By a News Reporter-Staff News Editor at Clinical Trials Week MediVector, Inc. announced it has successfully completed enrollment in two FAVOR favipiravir Phase 3 studies in adults with uncomplicated influenza. The two studies enrolled 2,021 patients in participating clinics and practices in the Americas, Europe, Australia, New Zealand and South A
3/2/15 - New Clinical Trials and Studies Findings from Osaka Medical Center for Cancer and Cardiovascular Diseases Reported [A multi-institution phase II...
New Clinical Trials and Studies Findings from Osaka Medical Center for Cancer and Cardiovascular Diseases Reported. By a News Reporter-Staff News Editor at Clinical Trials Week Current study results on Clinical Research have been published. According to news originating from Osaka, Japan, by NewsRx correspondents, research stated, "...
3/2/15 - New Clinical Trials and Studies Study Findings Have Been Reported by Researchers at University of Basel Hospital (Biochemical markers for assessment...
New Clinical Trials and Studies Study Findings Have Been Reported by Researchers at University of Basel Hospital. According to news reporting from Basel, Switzerland, by NewsRx journalists, research stated, "Nutrition plays an important role in osteoporosis prevention and treatment. The news correspondents obtained a quote from the research from th
3/2/15 - New Managed Care Pharmacy Findings Has Been Reported by Investigators at HealthCore (Cost-Effectiveness Analysis of Allopurinol Versus Febuxostat in...
By a News Reporter-Staff News Editor at Clinical Trials Week New research on Drugs and Therapies is the subject of a report. According to news reporting from Wilmington, Delaware, by NewsRx journalists, research stated, "Gout is a chronic inflammatory condition associated with poor urate metabolism. Treatment success was defined as patient achiev
3/2/15 - New Pharmacology and Therapeutics Findings from University of Montpellier I Described (Targeting the genetic alterations of the PI3K-AKT-mTOR...
New Pharmacology and Therapeutics Findings from University of Montpellier I Described. By a News Reporter-Staff News Editor at Clinical Trials Week Researchers detail new data in Drugs and Therapies. According to news reporting originating in Montpellier, France, by NewsRx journalists, research stated, "Urothelial carcinoma of the bladder is the
3/2/15 - New Post-Trial Research Study Findings Recently Were Reported by Researchers at Monaldi Hospital (Single-Access Laparoscopic Rectal Resection Versus...
New Post-Trial Research Study Findings Recently Were Reported by Researchers at Monaldi Hospital. According to news reporting from Naples, Italy, by NewsRx journalists, research stated, "Single-access laparoscopic surgery is not used routinely for the treatment of colorectal disease. The news correspondents obtained a quote from the research from..
3/2/15 - NIH-sponsored HIV vaccine trial launches in South Africa
By a News Reporter-Staff News Editor at AIDS Vaccine Week A clinical trial called HVTN 100 has been launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in study participants. The HVTN 100 vaccine regimen was designed to provide greater protection than the RV144 regimen and has
3/2/15 - NIH-supported trials to evaluate long-acting injectable anti-retrovirals to prevent HIV
By a News Reporter-Staff News Editor at AIDS Weekly Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of
3/2/15 - ONYX -Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority of Kyprolis (carfilzomib) Over Velcade (Bortezomib) in Patients with Relapsed Multiple Myeloma
Release date- 27022015- Amgen and its subsidiary Onyx Pharmaceuticals, Inc., today announced the results from a planned interim analysis showing that the Phase 3 head-to-head clinical trial ENDEAVOR evaluating Kyprolis for Injection in combination with low-dose dexamethasone versus Velcade and low-dose dexamethasone met the primary endpoint of...
3/2/15 - OTSUKA -First-ever treatment approved in Canada for adults living with ADPKD, a life-threatening kidney disease
Release date- 27022015- Otsuka Pharmaceutical Co., Ltd. and its affiliate Otsuka Canada Pharmaceutical Inc. announce that Health Canada has approved JINARC as the first pharmaceutical agent for the treatment of autosomal dominant polycystic kidney disease. The Health Canada approval of JINARC is based on the results of the pivotal Phase 3 randomize
3/2/15 - PAREXEL Simplifies Patient Recruitment And Study Start-Up Timelines Through Innovative Site Alliance Network
By a News Reporter-Staff News Editor at Clinical Trials Week PAREXEL International Corporation, a leading global biopharmaceutical services provider, announced the continued expansion of its clinical trial site alliance network, an extensive network of investigator sites and Site Management Organizations that enables PAREXEL to quickly access and
3/2/15 - Patent Issued for Fulvestrant Nanosphere/Microsphere and Preparative Method and Use
By a News Reporter-Staff News Editor at Pharma Business Week Xi'an Libang Pharmaceutical Technology Co., Ltd. has been issued patent number 8956659, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. This patent was filed on October 17, 2013 and was published online on February 17, 2015. From the background in
3/2/15 - Pfizer Announces FDA Acceptance for Review of a New Drug Application for ALO-02 oxycodone hydrochloride and naltrexone hydrochloride
By a News Reporter-Staff News Editor at Pharma Business Week Pfizer Inc. announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for ALO-02, extended-release capsules, an abuse-deterrent formulation opioid for the management of pain severe enough to require daily, around-the-clock, long-term opioid...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Lupus: What You Need to Know
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415